Stoke Therapeutics, Inc. (NASDAQ:STOK) Insider Sells $33,674.28 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the sale, the insider now owns 63,962 shares in the company, valued at approximately $554,550.54. This represents a 5.72 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Stoke Therapeutics Price Performance

NASDAQ STOK opened at $8.15 on Friday. Stoke Therapeutics, Inc. has a 1 year low of $6.29 and a 1 year high of $17.58. The stock has a market capitalization of $431.68 million, a PE ratio of -3.88 and a beta of 0.99. The business’s 50-day moving average is $9.47 and its 200 day moving average is $11.42.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million. As a group, equities research analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on STOK shares. HC Wainwright reissued a “buy” rating and issued a $47.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday. Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, March 18th. Chardan Capital reissued a “buy” rating and issued a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Stoke Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $23.00.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in STOK. KLP Kapitalforvaltning AS bought a new stake in Stoke Therapeutics in the fourth quarter worth $63,000. Teacher Retirement System of Texas purchased a new position in shares of Stoke Therapeutics in the 4th quarter worth about $113,000. China Universal Asset Management Co. Ltd. bought a new position in Stoke Therapeutics in the 4th quarter worth about $124,000. Tower Research Capital LLC TRC grew its position in Stoke Therapeutics by 70.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock valued at $132,000 after purchasing an additional 4,918 shares during the last quarter. Finally, Invesco Ltd. purchased a new position in Stoke Therapeutics in the fourth quarter worth about $133,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.